Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps
Novo Nordisk’s inventory retains falling even when the information is sweet, and CEO Mike Doustdar simply admitted why. Eli Lilly is thrashing Novo at its personal recreation.
Doustdar sat down with CNBC’s Jim Cramer this week to clarify the disconnect. Novo, well-known for its GLP-1 medicine Ozempic, raised its full-year gross sales steering on August 4, narrowing its projected annual decline from 8% to three% on the midpoint. Investors bought anyway. NVO shares dropped roughly 6% that day.
A Beat That Still Lost
Doustdar walked by the math on air. Novo slashed costs on Ozempic and Wegovy final yr to widen affected person entry, and quantity hasn’t caught up but to offset these cuts. He in contrast it to primary arithmetic. Halving a value means you want double the amount simply to interrupt even, and quantity by no means doubles on day one.
That hole between falling common income per prescription and rising affected person counts is strictly what has buyers nervous. Novo’s weight problems and diabetes medication now make up round 90% of its enterprise, in comparison with about 60% at Eli Lilly, leaving Novo extra uncovered to any pricing or aggressive shock in that single class.
Doustdar’s Concession
Oral Wegovy sits on the middle of this story. Novo launched the tablet model of its weight-loss drug in January, and it shortly turned one of many fastest-selling medication in pharmaceutical historical past. Doctors have already written extra than 5 million prescriptions for it, and 1.5 million sufferers now take it worldwide. That quantity makes Novo’s inventory response even tougher to clarify on the floor.
Cramer pressed him on why Eli Lilly’s stock rally has outrun Novo’s regardless of a much less dominant tablet. Doustdar didn’t dodge the query.
“Eli Lilly has been gaining market share. And they’re extra diversified than Novo Nordisk… there isn’t any secret that Lilly has been fairly profitable truly in having quantity uptake and market share uptake above and past Novo.”
He argued Lilly’s advert marketing campaign leans on an older, lower-dose model of Wegovy for comparability. Novo’s newer high-dose formulation matches Lilly’s efficacy, in line with Doustdar. That dispute sits on the middle of Novo’s lawsuit in opposition to Lilly over its promoting claims.
The Pill Still Wins on Paper
The inventory hunch hasn’t slowed the tablet’s numbers. In Novo’s personal trials, the tablet cuts weight by 17%, in opposition to 12% for Lilly’s rival tablet, although the 2 medication haven’t confronted off head-to-head. Doustdar referred to as it the best product launch in pharmaceutical historical past, a declare that’s arduous to dispute on quantity alone.
Doustdar is betting that two straight quarters of bettering developments will finally pull the inventory together with them. Whether that wager pays off is dependent upon a easy race. Patient quantity must outrun the value cuts quick sufficient to persuade Wall Street the reset is definitely over.
The put up Novo Nordisk CEO Concedes Eli Lilly’s Market-Share Gains as Stock Slumps appeared first on BeInCrypto.
